Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Regeneron and Bayer HealthCare announce results from a phase II study of VEGF Trap-Eye

Aug. 20, 2008

Recent patents describe new antiglaucoma agents

Aug. 19, 2008

Lexicon initiates formal preclinical development of LX-7101 for glaucoma

Aug. 14, 2008

Enrollment in phase IIb clinical trial for I-vation TA (MK-0140) suspended

Aug. 12, 2008

Novel agents for glaucoma reported in patent literature

Aug. 5, 2008

Othera submits IND application to FDA for OT-730 in glaucoma

July 31, 2008

NanoViricides reports excellent efficacy of EKC-Cide in first animal study

July 15, 2008

Alcon terminates development of anecortave acetate in AMD

July 14, 2008

Cerimon commences phase II Simulect study in noninfectious uveitis

July 10, 2008

Recent Allergan patent describes novel agents for glaucoma

July 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...